Physician profile
Roy A Kaplan
NPI 1215962451
$63,287.46
in general payments reported to CMS, 2019-2025
17 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $8,705 · 2023: $174 · 2024: $138 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $24,516.63 | 2019 | |
| Amgen INC. | $21,709.30 | 2019-2023 | Otezla, Enbrel, Amjevita |
| Horizon Therapeutics Plc | $15,029.15 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $462.28 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $255.36 | 2019-2020 | |
| Pfizer INC. | $253.06 | 2019 | |
| Ucb, INC. | $203.91 | 2019-2025 | Bimzelx |
| Abbvie INC. | $172.41 | 2019-2025 | |
| Genentech USA, INC. | $171.79 | 2019-2020 | |
| Lilly USA, LLC | $143.49 | 2019 | |
| Genzyme Corporation | $124.99 | 2019 | |
| Janssen Biotech, INC. | $90.43 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $63.04 | 2019 | |
| Merck Sharp & Dohme LLC | $30.04 | 2019 | |
| Medexus Pharma, INC. | $28.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $20.64 | 2019 | |
| Glaxosmithkline, LLC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.